



Chinese Pharmaceutical Association
Institute of Materia Medica, Chinese Academy of Medical Sciences

Acta Pharmaceutica Sinica B

www.elsevier.com/locate/apsb
www.sciencedirect.com



CORRECTION

Author correction to ‘VEGFR2-targeted antibody fused with IFN α 2b regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity’ [Acta Pharm Sin B 11 (2021) 420–433]



Pengzhao Shang^{a,†}, Rui Gao^{a,†}, Yijia Zhu^a, Xiaorui Zhang^a,
Yang Wang^a, Minji Guo^a, Hui Peng^b, Min Wang^a, Juan Zhang^{a,*}

^aAntibody Engineering Laboratory, School of Life Science & Technology, China Pharmaceutical University, Nanjing 210009, China

^bDepartment of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin 300050, China

The authors regret that there were some errors or inexact descriptions in the section of acknowledgments. “National Natural Science Foundation of China (Grant 81993223)” should be corrected to “National Natural Science Foundation of China(Grant 81973223)”.

The authors apologize for any inconvenience caused to the journal and readers.

DOI of original article: <https://doi.org/10.1016/j.apsb.2020.09.008>.

*Corresponding author.

E-mail address: zhangjuan@cpu.edu.cn (Juan Zhang).

[†]These authors made equal contributions to this work.

Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

<https://doi.org/10.1016/j.apsb.2024.02.014>

2211-3835 © 2024 Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.